What Lyell Immunopharma, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 2 | 4 |
| Sells | 9 | 29 |
| Total trades | 11 | 41 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 4,642,524 | 5,655,454 |
| Disposed | 14,135 | 256,569 |
| Net activity | +4,628,389 | +5,398,885 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Lee Gary K. | Chief Scientific Officer | Nov 10 | Sale for tax withholding · S | −129 | $15.93 | −$2.05K | 16,091 |
| Hill Stephen J. | Chief Operating Officer | Nov 10 | Sale for tax withholding · S | −88 | $15.93 | −$1.4K | 16,728 |
| Bulis Veronica Sanchez | VP, Corporate Controller | Nov 10 | Sale for tax withholding · S | −416 | $15.93 | −$6.63K | 14,383 |
| Seely Lynn | President and CEO | Nov 10 | Sale for tax withholding · S | −545 | $15.93 | −$8.68K | 63,354 |
| Arch Venture Partners IX, Llc | 10% owner | Nov 04 | Open-market buy · P | +2,321,262 | $10.77 | +$25M | 3,747,790 |
| Arch Venture Fund XIII, L.p. | 10% owner | Nov 04 | Open-market buy · P | +2,321,262 | $10.77 | +$25M | 3,747,790 |
| Aguirre Jarrad Mattieu | Chief Medical Officer | Oct 12 | Sale for tax withholding · S | −422 | $8.63 | −$3.64K | 19,857 |
| Shook David | Chief Medical Officer | Sep 10 | Sale for tax withholding · S | −500 | $12.70 | −$6.35K | 20,423 |
| Seely Lynn | President and CEO | Aug 21 | Sale for tax withholding · S | −9,589 | $15.54 | −$149K | 63,899 |
| Hill Stephen J. | Chief Operating Officer | Aug 21 | Sale for tax withholding · S | −989 | $15.54 | −$15.4K | 16,816 |
| Lee Gary K. | Chief Scientific Officer | Aug 21 | Sale for tax withholding · S | −1,457 | $15.54 | −$22.6K | 16,220 |
| Lee Gary K. | Chief Scientific Officer | Aug 10 | Sale for tax withholding · S | −131 | $14.34 | −$1.88K | 17,677 |
| Seely Lynn | President and CEO | Aug 10 | Sale for tax withholding · S | −390 | $14.34 | −$5.59K | 73,488 |
| Bulis Veronica Sanchez | VP, Corporate Controller | Aug 10 | Sale for tax withholding · S | −621 | $14.34 | −$8.91K | 14,799 |
| Hill Stephen J. | Chief Operating Officer | Aug 10 | Sale for tax withholding · S | −89 | $14.34 | −$1.28K | 17,805 |
| Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Jul 27 | Other Transaction · J | −38,500 | — | — | 2,818,980 |
| Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Jul 27 | Other Transaction · J | −44,000 | — | — | 2,774,980 |
| Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Jul 17 | Open-market sale · S | −10 | $13.70 | −$137 | 2,857,480 |
| Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Jul 16 | Open-market sale · S | −10 | $13.73 | −$137 | 2,857,490 |
| Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Jun 29 | Other Transaction · J | −76,000 | — | — | 2,857,500 |
Loading...